0.04Open0.04Pre Close0 Volume32 Open Interest0.50Strike Price0.00Turnover373.11%IV66.91%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type-0.0534Delta0.0898Gamma34.75Leverage Ratio-0.0033Theta-0.0001Rho-1.86Eff Leverage0.0004Vega
Aclaris Therapeutics Stock Discussion
On July 19, 2024, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced the sale of a portion of its future royalty payments and certain milestones related to OLUMIANT® (baricitinib) to OMERS...
Aclaris Therapeutics Shares Are Trading Higher After the Company Announced the Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for up to $31.5 Million
Aclaris Therapeutics Inc - Receives $26.5M Upfront Payment
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Aclaris Therapeutics (NASDAQ: ACRS) has announced the sale of a portion of its future royalty payments and certain milestones for OLUMIANT® (baricitinib) to OMERS Life Sciences for up to $31.5 million. The deal includes a $26.5 million upfront payment and up to $5.0 million in potential milestone payments based on OLUMIANT sales in 2024. Thi...
No comment yet